Drug ID: 1d00000009
Drug Name: Acamprosate
Generic Names: Acamptass | Acmacal tab | Acamprol tab | Campral
Category: Anti-alcoholic Agent
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category C:
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: The dose depends on patient’s body weight. The recommended dose is two 333 mg tablets (each dose should total to 666 mg) taken three times daily.
Recommended In: This medication is an anti-alcoholic agent. It is used to prevent the need for alcohol in people who have stopped drinking alcohol. It reduces the desire to consume alcohol.
Directions For Use: It comes as a tablet to take by mouth, three times per day, with or without meals.
Storage: Store it at room temperature (15-30°C), and in an airtight container.
Dosage Forms: Tablet |
Side Effects: Body as a Whole- Accidental injury, weakness, headache, feeling shortness of breath, abdominal pain, back pain, infection and burning or numbness in the hands, feet, arms, or legs.
Central Nervous System- Anxiety, depression, dizziness, dry mouth, sleeplessness, tingling, drowsiness, decreased libido (sexual pleasure), memory loss, abnormal thinking, suicide attempt and tremor.
Heart- Palpitations, syncope (consciousness loss), vasodilatation, high/low blood pressure, fast heart rate, bleeding, chest pain, varicose vein, sudden heart attack, inflammation of blood vessels and postural hypotension (fall in the blood pressure when the person stands up suddenly).
Gastrointestinal- Loss of appetite, diarrhea, flatulence, nausea, vomiting, blood vomiting, indigestion, constipation, increased appetite, inflammation of stomach, difficulty in swallowing, eructation, gastrointestinal bleeding, inflammation of pancreas and rectal bleeding.
Endocrine System- Decrease in thyroid hormone.
Blood - Anemia, easy bruising, eosinophilia, increase in lymphocytes and decrease in platelets.
Metabolic - Peripheral edema, weight gain, weight loss, hyperglycemia, increase in liver enzyme, gout, thirst, vitamin deficiency and excess bilirubin in blood.
Liver- Liver inflammation.
Skin- Itching, sweating, rash, pimples, hair loss, hive and dry skin.
Eye and ENT- Abnormal vision, taste perversion, ringing in the ear, poor vision or vision abnormalities and photophobia (sensitive to light).
Genitourinary- Impotence, irregular periods, urinating less than usual or not at all, urinary tract infection, abnormal sexual function, urinary incontinence and vaginal inflammation.
Miscellaneous- Fever, sleep problems, intentional overdose, malaise (discomfortness), allergic reaction, abscess, neck pain, hernia (swelling or projection of an organ), intentional injury, flu syndrome, chest pain and chills.
In Case of Overdose: In all reported cases of acute overdosage with Acamprosate (total reported doses of up to 56 grams of acamprosate calcium), the only symptom that could be reasonably associated with Acamprosate was diarrhea. Hypercalcemia has not been reported in cases of acute overdose. A risk of hypercalcemia should be considered in chronic overdosage only. Treatment of overdose should be symptomatic and supportive.
Avoid If: Caution should be exercised in patients with history of kidney disease, severe allergic reactions, patient under treatment with antidepressant, any planned surgery, elderly, children, during pregnancy and breastfeeding.
Patient may develop with suicidal thoughts, watch them carefully.
It may affect thinking ability or coordination, do not drive a car or operate machinery while taking this medication.
Avoid alcohol consumption.
Acamprosate will not treat or prevent alcohol withdrawal symptoms
Drug Interaction: Acamprosate does not affect the pharmacokinetics of alcohol. The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed.